149 related articles for article (PubMed ID: 7579557)
1. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses.
Garcia P; Braguer D; Carles G; Briand C
Anticancer Drugs; 1995 Aug; 6(4):533-44. PubMed ID: 7579557
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
de Ines C; Leynadier D; Barasoain I; Peyrot V; Garcia P; Briand C; Rener GA; Temple C
Cancer Res; 1994 Jan; 54(1):75-84. PubMed ID: 8261466
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines.
Garcia P; Braguer D; Carles G; el Khyari S; Barra Y; de Ines C; Barasoain I; Briand C
Cancer Chemother Pharmacol; 1994; 34(4):335-43. PubMed ID: 7913421
[TBL] [Abstract][Full Text] [Related]
4. Nordihydroguaiaretic acid, of a new family of microtubule-stabilizing agents, shows effects differentiated from paclitaxel.
Nakamura M; Nakazawa J; Usui T; Osada H; Kono Y; Takatsuki A
Biosci Biotechnol Biochem; 2003 Jan; 67(1):151-7. PubMed ID: 12619686
[TBL] [Abstract][Full Text] [Related]
5. 'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Rosenblum MD; Shivers RR
Comp Biochem Physiol C Toxicol Pharmacol; 2000 Jan; 125(1):121-31. PubMed ID: 11790336
[TBL] [Abstract][Full Text] [Related]
6. Structural intermediates in the assembly of taxoid-induced microtubules and GDP-tubulin double rings: time-resolved X-ray scattering.
Diaz JF; Andreu JM; Diakun G; Towns-Andrews E; Bordas J
Biophys J; 1996 May; 70(5):2408-20. PubMed ID: 9172767
[TBL] [Abstract][Full Text] [Related]
7. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
8. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
9. Antimicrotubular and cytotoxic activity of geiparvarin analogues, alone and in combination with paclitaxel.
Miglietta A; Bocca C; Gabriel L; Rampa A; Bisi A; Valenti P
Cell Biochem Funct; 2001 Sep; 19(3):181-9. PubMed ID: 11494307
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of docetaxel (Taxotere).
Lavelle F; Bissery MC; Combeau C; Riou JF; Vrignaud P; André S
Semin Oncol; 1995 Apr; 22(2 Suppl 4):3-16. PubMed ID: 7740328
[TBL] [Abstract][Full Text] [Related]
11. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
12. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.
Fromes Y; Gounon P; Veitia R; Bissery MC; Fellous A
J Protein Chem; 1996 May; 15(4):377-88. PubMed ID: 8819014
[TBL] [Abstract][Full Text] [Related]
13. Role of taxoids in head and neck cancer.
Schrijvers D; Vermorken JB
Oncologist; 2000; 5(3):199-208. PubMed ID: 10884498
[TBL] [Abstract][Full Text] [Related]
14. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation.
Honore S; Kamath K; Braguer D; Wilson L; Briand C; Jordan MA
Mol Cancer Ther; 2003 Dec; 2(12):1303-11. PubMed ID: 14707271
[TBL] [Abstract][Full Text] [Related]
15. [Modification of the response to paclitaxel of human differentiated colon cancer line after long-term treatment at very low dose].
Carles G; Braguer D; Rognoni JB; Roccabianca M; Marvaldi J; Briand C
Bull Cancer; 1996 Feb; 83(2):135-8. PubMed ID: 8652907
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4.
el Khyari S; Bourgarel V; Barra Y; Braguer D; Briand C
Biochem Biophys Res Commun; 1997 Feb; 231(3):751-4. PubMed ID: 9070886
[TBL] [Abstract][Full Text] [Related]
17. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
[TBL] [Abstract][Full Text] [Related]
18. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel: a review of its pharmacology and clinical activity.
Trudeau ME
Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
[TBL] [Abstract][Full Text] [Related]
20. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.
Escuin D; Kline ER; Giannakakou P
Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
